Bezopasyen li dlitelnyy priyom alfa-lipoevoy kisloty (ALA)?
Alfa-lipoevaya kislota (ALA) - eto estestvennoye soyedineniye, kotoroye funktsioniruyет kak kofaktor v mitokhondrialnom energeticheskom metabolizme. Kak dobavka ona prodayotsya blagodarya antioxidantnym svoystvam i privlekla vnimaniye pri podderzhke urovnya sakhara v krovi, zdorovya nervov i protivostareniya. No po mere rosta interesa k khronicheskoy supplementatsii voznikayet vopros: bezopasyen li dlitelnyy priyom ALA?
Chto pokazyvayut dolgovremennyye issledovaniya
Bolshinstvo klinicheskikh ispytaniy ALA prodolzhalis ot 3 do 6 mesyatsev, menshaya chast - do 2 let. Dvukhletneye randomizirovannoye kontroliruyemoye ispytaniye u patsiyentov s legkimi kognitivnymi narusheniyami obnaruzhilo, chto ALA khorosho perenosilas bez serezhnykh neblagopriyatnykh sobytiy (Hager et al., 2007). Meta-analiz ispytaniy prodolzhalnostyu do 6 mesyatsev pokazal, chto priyom ALA byl svyazan s snizheniyem sakhara v krovi natoshchak i pokazateley insulinorezistentnosti, s blagopriyatnym profilem bezopasnosti (Akbari et al., 2018).
Serёznyy vred ot ALA v standartnykh dozakh vstrechayetsya v opublikovannoy literature redko. Naibolee chasto soobshchayemyye pobochnyye effekty svyazany s ZhKT: toshnota, diskomfort v zheludke i inogda kozhnyye sypi. Oni, kak pravilo, legkiye i zavisyat ot dozy.
Verkhniye bezopasnyye predely so vremenem
Evropeyskiye i amerikanskiye regulyatornyye organy ne ustanovili oFitsialnyy dopustimyy verkhney predel potrebleniya dlya ALA, tak kak dokazatelskaya baza nedostatochna dlya yego opredeleniya. Dozy, ispolzuyemyye v issledovaniyakh, shiroko vary. Issledovaniya pri nevrologicheskikh zabolevaniyakh ispolzovaly bOlshiye kolichestva za boliye korotkiye periody, a dolgovremennyye ispytaniya, kak pravilo, ostanavalis v boliye konservativnom diapazone. Pobochnyye effekty so storony ZhKT uchashchayutsya pri uvelichenii dozy, i nekotoryye issledovateli rekomenduyut prinimat ALA s edoy dlya umensheniya razdrazheniya zheludka.
Yesli vy rassmatrivayete dlitelnoye primeneniye, prakticheskim podkhodom budet ostavatsya v predelakh diapasonov, izuchennykh v opublikovannykh ispytaniyakh, i sledit za reaktsiyey vashego organizma. Na maxfit.ee dostupny produkty, takiye kak NOW Alpha Lipoic Acid 250mg 60 veg caps, NOW Alpha Lipoic Acid 100mg 60 veg caps i MST Alpha Lipoic Acid 200mg + vitamin C 60caps, ch'i dozy sootvetstvuyut kolichestvam, izuchennym v kratkosrochnykh klinicheskikh issledovaniyakh.
Nuzhen li tsiklicheskiy priyom?
Kontseptsiya tsiklicheskogo priyoma ALA - priyom neskolk nedelyu, zatem pauza - obsuzhdata sya v fitness-soobshchestvakh, no net klinicheskikh dokazatelstv togo, chto tsiklicheskost neobkhodima ili chto nepreryvnoye primeneniye priv odit k tolerantnosti ili oslableniyu effekta. Kazetsya, chto ALA ne reguliruyet svoi metabolicheskiye puti so vremenem tak, kak eto delayut nekotoryye stimulyatory.
Tem ne meneye otsutstviye dolgovremmennykh dannykh o bezopasnosti svyshe 2 let oznachayet, chto my ne mozhem s uverennostyu skazat, chto bessrochnoye primeneniye ne nesёt riskov. Konservativnyy podkhod predusmatrivayet periodicheskuyu pereotsenku togo, otвechayet li dobavka vashim tselyam.
Monitoring pri dlitelnom priyome
Yesli vy prinimayte ALA nepreryvno, stoit uchost neskolko aspektov:
- Sakhar v krovi: ALA mozhet povyshat chuvstvitelnost k insulinu (Akbari et al., 2018). Yesli vy prinimayte lekarstva ot diabeta ili dlya kontrolya sakhara, vazhen regulyarnyy monitoring i konsultatsiya s vrachom.
- Funktsiya shchitovidnoy zhelezy: Yest nekotoryye doklinicheskiye svidetelstva togo, chto ochen vysokiye dozy ALA mogut vzaimodeystvovat s metabolizmom tireoydnykh gormonov, khotya eto ne bylo posledovatelno prodemonstrirovano v klinicheskikh ispytaniyakh pri obychnykh dobavochnykh dozakh.
- Status biotina: ALA i biotin razdelyayut transportnyye mekhanizmy. Teoreticheski, ochen vysokiye dozy ALA pri dlitelnom primenenii mogut vliyat na dostupnost biotina, khotya eto schitayetsya nezachitelnym pri tipichnykh dozakh.
Chestnyy verdikt
Dlya bolshinstva zdorovykh vzroslykh, ispolzuyushchikh ALA v dozakh, izuchennykh v klinicheskikh ispytaniyakh, imeyushchiyesya dokazatelstva podtverzhdayut razumnyy kratkosrochnyy i srednesrochnyy profil bezopasnosti. Dolgovremennyye dannyye svyshe 2 let ogranicheny, poetomu absoluytnoye uverennost v bezopasnosti bessrochnogo primeneniya nevozmozhna. Pobochnyye effekty, kak pravilo, legkiye i svyazany s ZhKT. Tsiklicheskost ne trebuyet dokazatelstv. Yesli u vas diabet, zabolevaniya shchitovidnoy zhelezy ili vy prinimayte lekarstva, prokonsuliruytes s vrachom pered nachalom dlitelnoy supplementatsii.
Izuchite kategoriya alfa-lipoevaya kislota (ALA) na maxfit.ee, chtoby nayti produkty, sootvetstvuyushchiye vashim predpochteniyam po dozirovaniyu.
ChZV
Mozhno li prinimat alfa-lipoevuyu kislotu (ALA) kazhdy den godami?
Klinicheskiye ispytaniya prodolzhitelnostyu do 2 let obnaruzhili khoroshuyu perenosimost ALA v izuchennykh dozakh. Dannyye svyshe 2 let ogranicheny, poetomu ostayotsya neyasnym, bezopasno li deystvitelno bessrochnoye ezhednevnoye primeneniye. Razumna periodicheskaya otsenka neobkhodimosti produkta.
Vyzyvayet li alfa-lipoevaya kislota (ALA) sereznyye pobochnyye effekty?
Serёznyye neblagopriyatnyye effekty v klinicheskikh issledovaniyakh soobshchayutsya redko. Naiboleye chastymi pobochnymi effektami yavlyayutsya legkiye problemy s ZhKT, takiye kak toshnota i diskomfort v zheludke, osobenno pri bolee vysokikh dozakh. Priyom ALA s edoy mozhet umenshit eti effekty.
Nuzhno li periodicheski dyelat pereryvy v priyome alfa-lipoevoy kisloty (ALA)?
Net klinicheskikh dokazatelstv togo, chto tsiklicheskost trebuetsya. ALA ne proyavlyayet tolerantnosti tak, kak eto mogut dyelat stimulyatory. Odnako, yesli vy ispolzuyete yeyo dlitelno, razumna periodicheskaya pereotsenka vashikh tseley i prodolzhayushcheysya potrebnosti.
Ssylki
Hager, K., Marahrens, A., Kenklies, M., Riederer, P., & Munch, G. (2007). Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Archives of Gerontology and Geriatrics, 45(3), 302-310.
Akbari, M., Ostadmohammadi, V., Tabrizi, R., Lankarani, K. B., Esmaillzadeh, A., Nematollahi, P., & Asemi, Z. (2018). The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Metabolism, 87, 56-69.
